Skip to content
Subscriber Only
Markets
Deals

CSPC Pharma Slumps on Speculation Drug Is on China Watch List

  • Stroke treatment compound makes up 20% of sales: fund manager
  • Possible provincial move comes as drug-cost cuts sought
Tablets are arranged for a photograph in Tokyo, Japan.
Photographer: Kiyoshi Ota/
Updated on

CSPC Pharmaceutical Group Ltd.’s shares logged their biggest decline since Feb. 19 on speculation that a component of the Chinese drugmaker’s key product has been put on a government watch list.

The possible inclusion of the substance, butylphthalide, on the watch list in China’s eastern Zhejiang province would mean the local government would closely monitor its usage.